We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Seven months after Prevail Therapeutics launched the New York-based company has secured $75 million in Series A financing to support the development of gene therapies